CLINICAL TRIALS PROFILE FOR COSELA
✉ Email this page to a colleague
All Clinical Trials for COSELA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04799249 ↗ | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) | Recruiting | G1 Therapeutics, Inc. | Phase 3 | 2021-04-15 | This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or second-line treatment for locally advanced unresectable/metastatic TNBC. |
| NCT04863248 ↗ | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) | Recruiting | G1 Therapeutics, Inc. | Phase 2 | 2021-04-16 | This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with mNSCLC treated in the 2nd or 3rd line setting. |
| NCT04887831 ↗ | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab | Recruiting | G1 Therapeutics, Inc. | Phase 2 | 2021-06-04 | This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in patients receiving first-line treatment for advanced/metastatic bladder cancer. |
| NCT06027268 ↗ | Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer | Recruiting | G1 Therapeutics, Inc. | Phase 2 | 2024-01-10 | The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer. The main questions it aims to answer are: - to evaluate the anti-cancer efficacy (assess how well it works) - to evaluate the safety and tolerability (how well the body can handle the treatment) of this combination of anti-cancer therapy |
| NCT06027268 ↗ | Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer | Recruiting | Merck Sharp & Dohme LLC | Phase 2 | 2024-01-10 | The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer. The main questions it aims to answer are: - to evaluate the anti-cancer efficacy (assess how well it works) - to evaluate the safety and tolerability (how well the body can handle the treatment) of this combination of anti-cancer therapy |
| NCT06027268 ↗ | Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer | Recruiting | Wake Forest University Health Sciences | Phase 2 | 2024-01-10 | The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer. The main questions it aims to answer are: - to evaluate the anti-cancer efficacy (assess how well it works) - to evaluate the safety and tolerability (how well the body can handle the treatment) of this combination of anti-cancer therapy |
| NCT07255612 ↗ | Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) | NOT_YET_RECRUITING | Sun Yat-sen University | PHASE2 | 2026-11-04 | Triple negative breast cancer (TNBC) has attracted much attention due to its young age of onset, high aggressiveness, lack of clear therapeutic targets and poor clinical prognosis.Eribulin is a novel non-taxane anti-microtubule inhibitor with unique microtubule and non-microtubule anti-tumor mechanism.Myelosuppression is the cause of many cancer chemotherapy-related adverse events, such as infections, sepsis, bleeding, and fatigue, resulting in delayed hospital stays or the need for treatment with hematopoietic growth factors, blood transfusions, and more.In addition, myelosuppression usually leads to a lower dose or longer interval of chemotherapy, which reduces the intensity of chemotherapy and affects the benefit of chemotherapy for patients.Trilaciclib is a highly potent, selective and reversible CDK4/6 inhibitor that protects bone marrow by protecting hematopoietic stem cells and progenitor cells (HSPCs) during systemic chemotherapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for COSELA
Condition Name
Clinical Trial Locations for COSELA
Trials by Country
Clinical Trial Progress for COSELA
Clinical Trial Phase
Clinical Trial Sponsors for COSELA
Sponsor Name
